Mabylon AG is a clinical-stage biotechnology company focused on discovering and engineering novel antibody therapeutics for allergy, inflammation, and neurology. They leverage a technology platform that rapidly identifies and clones human-derived or immunized animal antibodies from diverse immune repertoires. Mabylon aims to select the best functional, therapeutically relevant antibody products to address unmet medical needs in these areas.